✦ LIBER ✦

Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer

✍ Scribed by David Thompson; Douglas C. A. Taylor; Eduardo L. Montoya; Eric P. Winer; Stephen E. Jones; Milton C. Weinstein

Book ID: 109078653
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 171 KB
Volume: 10
Category: Article
ISSN: 1098-3015
DOI: 10.1111/j.1524-4733.2007.00190.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of switching to exeme

Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer

✍ Nancy A. Risebrough; Shailendra Verma; Maureen Trudeau; Nicole Mittmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

## Abstract ## BACKGROUND. Sequential tamoxifen/exemestane therapy reportedly improves disease‐free survival in women with primary breast cancer compared with continued tamoxifen therapy. The objective of the current study was to assess the cost‐effectiveness of switching to exemestane after 2 to

Cost-effectiveness of exemestane versus

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3

✍ Jonas Lundkvist; Nils Wilking; Stig Holmberg; Linus Jönsson 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 368 KB

Cost-effectiveness of letrozole versus t

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective

✍ Thomas E. Delea; Khalid El-Ouagari; Jonathan Karnon; Oleg Sofrygin 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 301 KB

Cost-effectiveness analysis of screening

Cost-effectiveness analysis of screening modalities for breast cancer in Japan with special reference to women aged 40–49 years

✍ Koji Ohnuki; Shinichi Kuriyama; Narumi Shoji; Yoshikazu Nishino; Ichiro Tsuji; N 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

Comparison of anastrozole versus tamoxif

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer : The pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial

✍ Luigi Cataliotti; Aman U. Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract ## BACKGROUND The Pre‐Operative “Arimidex” Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0‐2, M0), or potentially operable (T4b, N0‐2, M0) br

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB